|
WO2021072325A1
|
|
Compositions of ajulemic acid and uses thereof
|
|
WO2021067834A1
|
|
Cannabinoids and uses thereof
|
|
WO2021021543A1
|
|
Compositions and methods for attenuating side effects of immune checkpoint inhibitor therapy
|
|
CA3101626A1
|
|
Cannabinoids and uses thereof
|
|
WO2019079677A1
|
|
Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol
|
|
WO2017190070A1
|
|
Methods for the treatment of infection
|
|
US2017022179A1
|
|
Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
|
|
KR20160002709A
|
|
Ultrapure tetrahydrocannabinol-11oic acids
|
|
HUE047419T2
|
|
Tetrahydrocannabinol-11-oic acids for use in treating fibrotic diseases
|
